Benedito A. Carneiro

Also affiliated with Oklahoma State University Oklahoma City, Lifespan

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

1in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 8 papers. Top paper: “Androgen receptor-independent prostate cancer: an emerging clinical entity”.

Androgen receptor-independent prostate cancer: an emerging clinical entity

Cancer Biology & Therapy(2018)10.1080/15384047.2018.1423926

N/A

0.649DataRank · unranked

14 citations

Anthony E. Mega, Benedito A. Carneiro, Ilyas Sahin

Metastatic renal cell carcinoma to the pancreas and other sites—a multicenter retrospective study

EClinicalMedicine(2023)10.1016/j.eclinm.2023.102018

N/A

0DataRank · unranked

26 citations

Junxiao Hu, Benoit Beuselinck, Justine Panian, Nicole Weise, Nazlı Dizman +23 more

GSK-3 Inhibitor Elraglusib Enhances Tumor-Infiltrating Immune Cell Activation in Tumor Biopsies and Synergizes with Anti-PD-L1 in a Murine Model of Colorectal Cancer

International Journal of Molecular Sciences(2023)10.3390/ijms241310870

N/A

0DataRank · unranked

25 citations

Anna D. Louie, Praveen R. Srinivasan, Christoph Schorl, Shaolei Lu, David Silverberg +9 more

GSK-3 inhibitor elraglusib enhances tumor-infiltrating immune cell activation in tumor biopsies and synergizes with anti-PD-L1 in a murine model of colorectal cancer

bioRxiv (Cold Spring Harbor Laboratory)(2023)10.1101/2023.02.07.527499

N/A

0DataRank · unranked

6 citations

Anna D. Louie, Praveen R. Srinivasan, Christoph Schorl, Shaolei Lu, David Silverberg +9 more

Therapeutic targeting of TRAIL death receptors

Biochemical Society Transactions(2023)10.1042/bst20220098

N/A

0DataRank · unranked

48 citations

Andrew George, Vida Tajiknia, Maryam Ghandali, Laura Jinxuan Wu, Yiqun Zhang +10 more

Variation in FOLFOX, FOLFIRI, and FOLFOXIRI effects on CD8+ T cell and PDL1 levels in MSS CRC patients.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.3526

N/A

0DataRank · unranked

0 citations

Andrew Elliott, Marzia Capelletti, Emil Lou, John L. Marshall, Heinz‐Josef Lenz +10 more

Expression Patterns of DLL3 across Neuroendocrine and Non-neuroendocrine Neoplasms Reveal Broad Opportunities for Therapeutic Targeting

Cancer Research Communications(2025)10.1158/2767-9764.crc-24-0501

N/A

0DataRank · unranked

14 citations

Andrew Elliott, Mark G. Evans, James Wacker, Kathleen M. Storey, Emily A. Egusa +14 more

GSK-3 inhibitor elraglusib (9-ING-41) to enhance tumor-infiltrating immune cell activation in tumor biopsies and synergize with anti-PD-L1 in a murine model of colorectal cancer.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.e15138

N/A

0DataRank · unranked

1 citations

Kelsey E. Huntington, Anna D. Louie, Praveen Srinivasan, Cristoph Schorl, Shaolei Lu +10 more